.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Pediatric Tumor
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Pediatric Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE City of Hope Medical Center | Phase 2/3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2/3 | BBB |
FILGRASTIM Barbara Ann Karmanos Cancer Institute | Phase 3 | BBB |
Carboplatin Seoul National University Hospital | Phase 2/3 | BBB |
Busulphan City of Hope Medical Center | Phase 2/3 | BBB |
View all 50 →
Same molecule, other indications
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →